C1orf57 Activators
Items 1 to 10 of 23 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
An mTOR inhibitor, Rapamycin leads to the inactivation of downstream targets implicated in protein synthesis and cell growth, potentially diminishing the activity of C1orf57 if it is involved in these mTOR-regulated processes. | ||||||
Resveratrol | 501-36-0 | sc-200808 sc-200808A sc-200808B | 100 mg 500 mg 5 g | $80.00 $220.00 $460.00 | 64 | |
Resveratrol can activate C1orf57 by interacting with cellular signaling pathways involved in its regulation. It may enhance C1orf57 expression or stability, contributing to its activation. | ||||||
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
A non-selective protein kinase inhibitor, Staurosporine inhibits a wide range of kinases. If C1orf57 function relies on phosphorylation events mediated by these kinases, its activity would be decreased as a result. | ||||||
Quercetin | 117-39-5 | sc-206089 sc-206089A sc-206089E sc-206089C sc-206089D sc-206089B | 100 mg 500 mg 100 g 250 g 1 kg 25 g | $11.00 $17.00 $110.00 $250.00 $936.00 $50.00 | 33 | |
Quercetin can indirectly activate C1orf57 by modulating intracellular processes or pathways that affect C1orf57 function. This compound may impact C1orf57 through its antioxidant or anti-inflammatory properties. | ||||||
Curcumin | 458-37-7 | sc-200509 sc-200509A sc-200509B sc-200509C sc-200509D sc-200509F sc-200509E | 1 g 5 g 25 g 100 g 250 g 1 kg 2.5 kg | $37.00 $69.00 $109.00 $218.00 $239.00 $879.00 $1968.00 | 47 | |
Curcumin can activate C1orf57 by influencing gene expression or post-translational modifications. It may regulate C1orf57 levels and activity through interactions with specific cellular factors. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
An ERK pathway inhibitor, PD 98059 prevents the activation of ERK1/2 by inhibiting MEK, which could lead to a decrease in C1orf57 activity if it is part of the ERK signaling cascade. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
A PI3K inhibitor, LY 294002 would lead to a reduction in AKT signaling, potentially diminishing C1orf57 activity if it is downstream of PI3K/AKT pathway. | ||||||
Sodium Butyrate | 156-54-7 | sc-202341 sc-202341B sc-202341A sc-202341C | 250 mg 5 g 25 g 500 g | $31.00 $47.00 $84.00 $222.00 | 19 | |
Sodium butyrate, a histone deacetylase inhibitor, can indirectly activate C1orf57 by altering chromatin structure and gene accessibility. This compound may enhance C1orf57 expression by promoting histone acetylation at its promoter region. | ||||||
Valproic Acid | 99-66-1 | sc-213144 | 10 g | $87.00 | 9 | |
Valproic acid, another histone deacetylase inhibitor, indirectly activates C1orf57 by enhancing histone acetylation. This modulation of epigenetic marks may contribute to increased C1orf57 expression. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
This inhibitor targets the p38 MAPK pathway. Inhibiting p38 MAPK could diminish C1orf57 activity if C1orf57 is involved in stress response pathways regulated by p38. | ||||||